Merck Expands Vaccine Partnership With Crucell
This article was originally published in The Pink Sheet Daily
Executive Summary
Cross-licensing deal allows Merck to further leverage the Dutch biotech’s technology.
You may also be interested in...
MedImmune Inks Deal For Crucell Preclinical Antibodies
Agreement gives firm exclusive rights to develop and market panel of antibodies for hospital-acquired bacterial infection.
MedImmune Inks Deal For Crucell Preclinical Antibodies
Agreement gives firm exclusive rights to develop and market panel of antibodies for hospital-acquired bacterial infection.
Merck To Incorporate Idera’s TLR Agonists Into Vaccine Program
Merck will pay Idera $20 million up front as part of deal.